The Board of Directors approved an increase in board size from eight to nine members and appointed Suzanne Topalian, M.D., as a Class III director effective October 27, 2026. Dr. Topalian will serve until the 2028 annual meeting and join the Science and Technology Committee. She receives standard non-employee director compensation including automatic equity grants. Vir Biotechnology is a biotechnology company focused on developing therapies for infectious diseases.
